Drug intelligence / Profile preview

CF-02

Development stage: Unknown
Lead developer: Cannaflos
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Intraperitoneal

Overview

CF-02 is a phytocannabinoid-based drug candidate being developed by Cannaflos. It is designed to modulate the endocannabinoid system (ECS) for the treatment of neuropathological conditions. As a cannabinoid-based finished drug, it utilizes plant-derived cannabinoids to target ECS receptors or enzymes, although the specific molecular target within the system has not been publicly disclosed. The candidate is currently in Phase 1 clinical development.

Targets

RELA (Nuclear Factor Kappa B Subunit p65)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)MEK

Beyond the preview

Go deeper on CF-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CF-02.

Explore the full profile